Lucentis (ranibizumab)

AAVIATE: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)

MR45625: Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD (2024-516924-32-00)

A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (clinicaltrials.gov)

Observation on the Efficacy of Ranibizumab Injection with 3+PRN Regimen Combined with PRP in the Treatment of DME (ChiCTR2500113346)

A single-arm, phase II clinical study of Sacituzumab Tirumotecan combined with Bevacizumab for the treatment of platinum-resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer (ChiCTR2500112955)

BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)

VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)

A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss (clinicaltrials.gov)

A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD (clinicaltrials.gov)

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (clinicaltrials.gov)

Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)

M-VIVA: Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (clinicaltrials.gov)